The aim of this study was to determine whether isradipine affects microalbuminuria and other biochemical parameters related to glucose and lipid metabolisms. 18 subjects, 40 to 73 years of age, with NIDDM for 0 to 21 years, blood pressure²140/90 mmHg in the absence of antihypertensive treatment, and persistent urinary albumin excretion rate (UAER) 30 to 300 mg/day, received sustained-release (SRO) formulation isradipine at dosages of 5 mg once daily for 3 months. The effects of isradipine on microalbuminuria, fasting plasma glucose, plasma lipids, plasma creatinin, uric acid, C-peptide, insulin, HbA 1c , fructosamine, systolic and diastolic blood pressure and heart rate were assayed. After 3 months of isradipine treatment, UAER fell from 72.5±40.2 to 52.9±39.5 mg/24 h (p
Isradipine, microalbuminuria, diabetic nephropathy, antihypertensive treatment.
SABUNCU, Tevfik; VURAL, Hüseyin; DALMAZ, Mahmut; NAZLIGÜL, Yaşar; KOÇYİĞİT, Abdurrahim; EREL, Özcan; and AVCI, Şenel (1998) "Metabolic Effects of Isradipine In NormotensiveNIDDM Patients With Microalbuminuria," Turkish Journal of Medical Sciences: Vol. 28: No. 6, Article 10. Available at: https://journals.tubitak.gov.tr/medical/vol28/iss6/10